Investigating the effect of alpha lipoic acid on the amount of saliva in head and neck cancer patients undergoing radiotherapy

Investigation The effect of alpha-lipoid acid on saliva rate of the patients underwent radiotherapy of head and neck cancers

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221219056864N1

Enrollment

Registered

2023-07-13

Start date

2023-07-23

Completion date

Unknown

Last updated

2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer patients undergoing cervical radiotherapy. ????????

Interventions

Intervention group: Patients using 300 mg alpha-phaliboic acid capsules under the name of Elbik by Raha Pharmaceutical Company twice a day for three months, and the control group of patients using pla

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age>18 Patients with head and neck cancers with a total radiation dose of 56-70 Gy

Exclusion criteria

Exclusion criteria: History of liver disease, diabetes, thyroid History of alcohol consumption Malnutrition Receiving any chemotherapy drugs History of salivary gland cancer History of treatment with alpha-lipoid acid for any other reason History of allergy to alpha-lipoid acid or other antioxidants and food supplements Consumption of iron products Pregnant or lactating women

Design outcomes

Primary

Measure	Time frame
The effect of alpha-boic acid on the amount of saliva in cancer patients undergoing head and neck radiotherapy. Timepoint: Before starting radiotherapy and 2-6-8-12 weeks after radiotherapy. Method of measurement: Collection of unstimulated saliva in the Falcon tube within 5 minutes.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHeidari Massume

Shahid Beheshti University of Medical Sciences

heydari.s370@yahoo.com+98 21 2242 7752

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026